GSK stock in focus after $2.2 billion Zantac settlement
Published on 11/12/2026 at 12:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSLitigation risk moves toward resolution
- GSK says the settlement covers 93% of outstanding Zantac cancer lawsuits.
- The agreement addresses a major legal overhang surrounding the former gastrointestinal medicine.
- Investors will continue to weigh litigation costs against GSK's pipeline and specialty-medicines strategy.
GSK says it has reached a USD 2.2 billion settlement that will resolve 93% of outstanding lawsuits alleging that its former gastrointestinal medicine Zantac caused cancer. The development was reported on Thursday, November 12, by pharmaphorum, which cited GSK's assessment of the agreement.
For GSK, the settlement addresses most of the remaining claims linked to Zantac, a drug that was withdrawn from the market in 2020 after concerns about possible cancer risks. The legal dispute has involved claims from patients who alleged that the medicine's active ingredient, ranitidine, could degrade into a potentially carcinogenic substance.
Financial and strategic implications
The settlement gives investors a clearer framework for assessing the company's litigation exposure, although the reported amount remains material for a pharmaceutical group managing a broad research and development portfolio. Resolving most claims can reduce uncertainty around future legal proceedings, but the agreement does not eliminate every Zantac-related case.
The litigation development arrives as GSK works to shift its growth profile toward specialty medicines, vaccines and a more productive late-stage pipeline. The company must balance legal payments and restructuring costs with investment in new medicines, particularly in oncology, respiratory disease, HIV and liver disease.
GSK stock traded at 22.83 euros on Lang & Schwarz at 12:34 CET on Thursday, November 12.
GSK plc at a glance
- Company: GSK plc
- ISIN: GB00BN7SWP63
- Ticker: GSK
- Latest quote: 22.83 euros on Lang & Schwarz, Thursday, November 12, 2026, at 12:34 CET
- Zantac settlement: USD 2.2 billion
- Claims addressed: 93% of outstanding lawsuits, according to GSK
UK equities remain a relevant backdrop for investors monitoring the FTSE 100.
